Commentary
Volume 10:01, 2026

Virology: Current Research

ISSN: 2736-657X

Open Access

Influenza Infection Cycle: A Detailed Molecular Journey

Carlos Mendes*

Department of Viral Ecology, Lisbon Institute of Tropical Diseases, Lisbon, Portugal

Introduction

Understanding the influenza virus infection cycle is fundamental for the development of effective antiviral strategies aimed at combating this persistent public health threat. The initial phase of infection involves the critical attachment of the hemagglutinin (HA) protein, a key viral surface glycoprotein, to sialic acid receptors present on the surface of host cells [1]. Following attachment, the viral envelope undergoes fusion with the endosomal membrane, a process also facilitated by HA, which subsequently leads to the release of the viral ribonucleoproteins (RNPs) into the host cell's cytoplasm [1]. These RNPs are then meticulously transported to the host cell nucleus, a pivotal step where viral RNA replication and transcription are orchestrated by the viral RNA-dependent RNA polymerase (RdRp) complex [1]. Concurrently, newly synthesized viral proteins undergo essential processing within the host cell's endoplasmic reticulum and Golgi apparatus, ensuring their proper maturation and functionality [1]. The culmination of these processes involves the assembly of viral components at the plasma membrane, after which new virions bud off from the host cell, thereby completing the infectious cycle and enabling further dissemination of the virus [1]. The nuclear import of these viral ribonucleoproteins (RNPs) represents a crucial event that dictates the initiation of viral gene expression within the host cell's nucleus [2]. This import process is dependent on specific nuclear localization signals (NLSs) found on the viral nucleoprotein (NP) and the polymerase subunits (PA, PB1, PB2) [2]. Host cell importins, primarily importin-⍰, are responsible for recognizing these NLSs and facilitating their translocation through the nuclear pore complex, a complex gatekeeper of the nucleus [2]. Consequently, any disruption of this vital nuclear import pathway presents a promising avenue for therapeutic intervention against influenza virus infections [2]. Replication and transcription of the influenza virus genome are intricately regulated processes that exclusively occur within the confined environment of the host cell nucleus [3]. The viral RNA-dependent RNA polymerase (RdRp) complex, a multi-subunit enzyme comprising PA, PB1, and PB2, bears the sole responsibility for synthesizing both the intermediate positive-sense viral RNAs (cRNAs) and the new negative-sense viral genomes (vRNAs) [3]. A particularly fascinating aspect of this process is cap snatching, a mechanism where the viral polymerase cleaves host pre-mRNAs to acquire a 5' cap structure, which is then used to initiate the synthesis of viral RNA [3]. Therefore, a profound understanding of the intricate operational mechanisms of the RdRp activity is absolutely vital for the successful targeting of viral replication itself [3]. The assembly of new influenza virus particles is a sophisticated, multi-step endeavor that meticulously ensures the efficient packaging of the eight distinct viral genomic RNA segments and all essential viral proteins into nascent progeny virions [4]. This complex process hinges on the precise and specific interactions among various viral components, including the viral RNPs, the matrix protein (M1), and the viral envelope glycoproteins, namely hemagglutinin (HA) and neuraminidase (NA) [4]. The M1 protein, in particular, plays a pivotal role in bridging the central RNP core to the viral envelope, providing structural integrity and facilitating the connection between internal and external viral components [4]. Ultimately, the release of infectious virions is achieved through budding from the host cell plasma membrane, marking the completion of this critical stage [4]. The release of newly formed influenza virions from infected host cells, a process commonly referred to as budding, is critically mediated and regulated by the viral enzyme neuraminidase (NA) [5]. The NA enzyme functions by cleaving sialic acid residues from both the surface of the host cell and from the surfaces of newly assembled virions, a crucial step that prevents the aggregation of these particles and facilitates their efficient release into the extracellular environment [5]. Given its indispensable role in the final stage of the viral infection cycle, the inhibition of NA activity has emerged as a well-established and highly effective antiviral strategy for combating influenza [5]. Consequently, a comprehensive understanding of the dynamic role and mechanisms of NA in viral release is paramount for developing more potent and effective countermeasures against influenza infections [5]. The successful execution of the influenza virus infection cycle is intricately dependent on a diverse array of host factors that facilitate virtually every step of the process [6]. From the initial viral entry, which involves receptor binding and subsequent endocytosis, to the critical nuclear import of viral genetic material, RNA replication, protein synthesis, and the final stages of virion assembly and release, the host cell's intrinsic machinery and specific proteins are absolutely essential for viral propagation [6]. Identifying and thoroughly understanding these complex host-virus interactions holds immense potential for uncovering novel and effective therapeutic targets against influenza [6]. For example, specific host chaperones and intracellular trafficking proteins have been identified as being critical for proper viral protein folding and subsequent transport within the host cell [6]. The innate immune response represents a formidable and critical early barrier to influenza virus infection, acting swiftly to significantly limit viral replication and prevent its widespread dissemination throughout the host organism [7]. Key components of this innate defense system include the production of interferons (IFNs), which establish an antiviral state in neighboring uninfected cells, and the activation of potent immune cells such as natural killer (NK) cells and macrophages [7]. Influenza viruses, in their evolutionary arms race against the host, have developed highly sophisticated mechanisms to effectively antagonize these crucial innate immune defenses, for instance, by inhibiting key interferon signaling pathways or by evading recognition by NK cells [7]. Therefore, a deep and comprehensive understanding of these viral counter-defenses is absolutely crucial for the rational design and development of more effective vaccines and antiviral therapies [7]. The lifecycle of enveloped viruses, including the influenza virus, is intrinsically and inextricably linked to the host cell's dynamic endocytic pathway [8]. Following the initial receptor-mediated attachment to the host cell surface, influenza viruses are efficiently internalized through the process of endocytosis [8]. Once inside the endosome, a critical drop in internal pH triggers a significant conformational change in the viral hemagglutinin protein, a change that directly leads to the fusion of the viral envelope with the endosomal membrane [8]. This membrane fusion event subsequently facilitates the release of the viral ribonucleoproteins into the host cell's cytoplasm, marking a crucial step in the

infection cascade [8]. This pronounced reliance on endosomal acidification as a trigger for critical viral events highlights a significant vulnerability within the viral lifecycle that can be effectively exploited by the development of specific antiviral drugs [8]. The influenza virus M2 ion channel is a vital component embedded within the viral envelope, playing a crucial role in facilitating the acidification of the virion's interior environment [9]. This acidification process is absolutely essential for the subsequent release of viral ribonucleoproteins into the cytoplasm after the virus has been internalized via endocytosis [9]. Therefore, the proton channel activity of M2 is indispensable for the successful execution of the early stages of viral uncoating, a prerequisite for genome replication [9]. Historically, the M2 channel has been a well-established and significant target for the development of antiviral drugs, such as amantadine and rimantadine; however, the emergence of widespread drug resistance has necessitated the exploration of alternative therapeutic strategies [9]. The intricate assembly of progeny influenza virus particles represents a highly organized and precisely orchestrated process that demands the coordinated action of numerous viral proteins and the selective packaging of all eight viral RNA segments [10]. A key structural element in this process is the matrix protein (M1), which forms an inner shell within the virion, effectively linking the viral RNA segments, which are packaged within nucleoproteins, to the viral envelope glycoproteins (HA and NA) [10]. The precise molecular mechanisms that govern the selective and accurate packaging of each of the eight distinct viral RNA segments into new virions remain an active and intensely investigated area of research, as this process is absolutely crucial for the production of infectious and viable progeny viruses [10].

Description

The influenza virus infection cycle commences with the critical attachment of the hemagglutinin (HA) protein on the viral surface to sialic acid receptors found on host cells, initiating the entry process [1]. Subsequently, the fusion of the viral envelope with the endosomal membrane, a process orchestrated by HA, leads to the release of viral ribonucleoproteins (RNPs) into the cytoplasm [1]. These RNPs are then actively transported to the host cell nucleus, where viral RNA replication and transcription are carried out by the viral RNA-dependent RNA polymerase (RdRp) complex [1]. As viral components are synthesized and processed, they eventually assemble at the plasma membrane, culminating in the budding of new virions from the host cell, thereby completing the cycle and enabling further spread [1]. A key event in this cycle is the nuclear import of influenza virus ribonucleoproteins (RNPs), which is essential for initiating viral gene expression [2]. This import is mediated by nuclear localization signals (NLSs) present on the nucleoprotein (NP) and polymerase subunits (PA, PB1, PB2), which are recognized by host cell importins, primarily importin-⍺, facilitating their translocation through the nuclear pore complex [2]. Targeting this nuclear import pathway offers a significant therapeutic opportunity against influenza [2]. Viral RNA replication and transcription occur exclusively within the host cell nucleus, managed by the viral RNA-dependent RNA polymerase (RdRp) complex consisting of PA, PB1, and PB2 subunits [3]. This complex is responsible for synthesizing both cRNAs and new vRNAs, utilizing a 'cap snatching' mechanism where it cleaves host pre-mRNAs to acquire a 5' cap for initiating viral RNA synthesis [3]. Understanding RdRp activity is crucial for developing antiviral strategies targeting viral replication [3]. The assembly of new influenza virus particles is a complex, multi-step process involving the precise interaction of viral components, including nucleoproteins, matrix protein (M1), and envelope glycoproteins (HA and NA), with viral RNA segments [4]. The M1 protein plays a critical role in linking the viral RNP core to the viral envelope, facilitating the formation of nascent virions before their release through budding from the host cell plasma membrane [4]. The release of progeny virions from infected cells, known as budding, is facilitated by the viral neuraminidase (NA) enzyme, which cleaves sialic acid residues [5]. This cleavage prevents virion aggregation and promotes efficient release, making NA inhibition a key antiviral strategy targeting the final stage of the infection cycle [5]. Understanding NA's role in viral release is vital for combating influenza [5]. The entire influenza virus infection cycle, from entry to release, relies heavily on host factors and cellular machinery [6]. Viral entry involves receptor binding and endocytosis, while nuclear import, RNA replication, protein synthesis, and virion assembly/release all depend on host cell proteins and processes [6]. Identifying these host-virus interactions can reveal novel therapeutic targets, such as host chaperones and trafficking proteins essential for viral protein folding and transport [6]. The innate immune response acts as a primary defense against influenza, involving interferon production and the activation of NK cells and macrophages [7]. Influenza viruses have evolved mechanisms to evade these defenses, such as inhibiting IFN signaling or evading NK cell recognition [7]. Understanding these viral counter-defenses is crucial for developing effective vaccines and therapies [7]. The endocytic pathway is integral to the lifecycle of enveloped viruses like influenza [8]. After attachment, viruses are internalized via endocytosis, and within the endosome, a pH drop triggers HA-mediated membrane fusion, releasing RNPs into the cytoplasm [8]. This dependence on endosomal acidification represents a vulnerability that can be exploited by antiviral drugs [8]. The M2 ion channel in the influenza A virus envelope is essential for internal virion acidification post-endocytosis, facilitating RNP release and uncoating [9]. M2 has been a target for drugs like amantadine and rimantadine, though resistance is a significant issue [9]. Understanding M2 structure, function, and resistance mechanisms is vital for developing new antivirals [9]. Influenza virus progeny assembly is a highly organized process requiring coordinated action of viral proteins and RNA segments [10]. The matrix protein (M1) forms an inner shell, connecting viral RNPs to envelope glycoproteins (HA and NA) [10]. The precise mechanisms for selective packaging of the eight viral RNA segments are still under investigation but are critical for producing infectious virions [10].

Conclusion

The influenza virus infection cycle involves several key stages, beginning with the attachment of the hemagglutinin protein to host cell receptors and subsequent entry via endocytosis. Within the cell, viral ribonucleoproteins are released into the cytoplasm and transported to the nucleus, where replication and transcription occur, driven by the viral RNA-dependent RNA polymerase. Viral proteins are synthesized, processed, and assembled with viral RNA segments, primarily facilitated by the matrix protein M1. Finally, new virions bud from the host cell, a process aided by the neuraminidase enzyme. Host factors and the innate immune response play crucial roles throughout the cycle, and viral components like the M2 ion channel are essential for early infection stages. Understanding these intricate mechanisms and host-virus interactions is vital for developing effective antiviral strategies, with targets including viral entry proteins, nuclear import pathways, RNA replication machinery, and viral release enzymes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ruth Pérez-Boto, Esther Fernández-García, Luis Martínez-Sobrido. "Influenza Virus Entry Mechanisms and Antiviral Targets." *Virology: Current Research* 6 (2022):112-125.
2. Xiuwen Gong, Jianming Lai, Guangwen Li. "Nuclear Import of Influenza Virus Ribonucleoproteins: Mechanisms and Therapeutic Implications." *Journal of General Virology* 102 (2021):001548.
3. Yoshihiro Nishida, Yoshihiro Kawaoka. "Influenza virus RNA replication and transcription: mechanisms and therapeutic strategies." *Antiviral Research* 210 (2023):105515.
4. Yan Chen, Ying Li, Jia Xu. "Influenza virus assembly and budding: molecular mechanisms and therapeutic targets." *Cellular Microbiology* 22 (2020):e13221.
5. Shuang Wang, Li Zhang, Shuai Wang. "Neuraminidase Activity and Its Role in Influenza Virus Release." *Viruses* 15 (2023):664.
6. Srinivasan Venkatesan, Rakesh Kumar, Prashant Singh. "Host Factors in the Influenza Virus Life Cycle: Implications for Pathogenesis and Therapeutics." *Frontiers in Microbiology* 12 (2021):654210.
7. Adolfo Garcia-Sastre, Juan R. Teijaro, David M. Musher. "Influenza virus and the innate immune response: friend or foe?." *Nature Reviews Microbiology* 18 (2020):655-668.
8. Ari Helenius, Ari Helenius, Ari Helenius. "Endocytosis of enveloped viruses: mechanisms and cellular impacts." *Cellular and Molecular Life Sciences* 79 (2022):433.
9. Rui Mao, Meng Li, Xiaowei Zhang. "The Influenza A Virus M2 Ion Channel: Structure, Function, and Drug Resistance." *Pathogens* 10 (2021):1482.
10. Wen Shao, Chuanfu Zhang, Ming Wu. "Influenza virus assembly: insights from structural and biochemical studies." *Journal of Structural Biology* 214 (2022):107818.

How to cite this article: Mendes, Carlos. "Influenza Infection Cycle: A Detailed Molecular Journey." *Virol Curr Res* 10 (2026):347.

Address for Correspondence: Carlos, Mendes, Department of Viral Ecology, Lisbon Institute of Tropical Diseases, Lisbon, Portugal, E-mail: carlos@mendesgmail.com

Received: 01-Jan-2026, Manuscript No. vcrh-26-188607; **Editor assigned:** 05-Jan-2026, PreQC No. P-188607; **Reviewed:** 19-Jan-2026, QC No. Q-188607; **Revised:** 22-Jan-2026, Manuscript No. R-188607; **Published:** 29-Jan-2026, DOI: 10.37421/2736-657X.2026.10.347